ORIGYN Foundation Receives Strategic Investment of $20M from World-Renowned Investors, including Bill Ackman’s Table Management, Polychain Capital, Paris Hilton, Coinko and Vectr Ventures
23.11.2021 17:38:00 EET | Business Wire | Press release
ORIGYN Foundation, the Swiss nonprofit dedicated to identifying, authenticating and unlocking the powers of ownership for objects of value, has today announced a strategic raise of $20 million. Investors in this round include Bill Ackman’s Table Management, Polychain Capital, Paris Hilton, Coinko, Vectr Ventures, Carter Reum, Div Turakhia, GD10 Ventures and more. Ahead of the foundation’s public token release, this private round now values ORIGYN at $300 million.
“We’re incredibly fortunate and excited to include so many influential names in this funding round. ORIGYN is unique in what it brings to this world. It’s a sign of support for what ORIGYN is trying to achieve—using technology to solve for identity, authenticity and proof of ownership. Our partners have seen the opportunity we provide to unlock value for owners and creators,” said Daniel Haudenschild, CEO of ORIGYN Entreprise SA, which is the operating entity of ORIGYN Foundation.
Founded in October of 2020, ORIGYN is led by its founding partners and council members Gian Bochsler, Vincent Perriard and Mike Schwartz, as well as by CEO Daniel Haudenschild. The foundation’s technology certifies and guarantees the authenticity of physical and digital items using advanced recognition and identification techniques created by leading experts in computer vision, artificial intelligence and decentralized infrastructure. It also unites the greatest contemporary players across select industries to protect, celebrate, elevate and reward creativity through its novel approach to NFTs.
ORIGYN currently operates the following industry verticals:
● ORIGYN Art is an exclusive community for the fine art market on the blockchain. This vertical establishes a connection between physical works of art and NFT certificates to create the ultimate marketplace experience for creators, industry professionals, collectors and enthusiasts.
● ORIGYN Collectibles is a revolutionary platform designed to empower individuals with shared passions to buy, sell, trade and experience collectors’ items. This vertical rewards and celebrates creativity by tokenizing certificates of ownership that verify the uniqueness and authenticity of physical collectibles.
● ORIGYN Digital Media is a comprehensive ecosystem built for media creators of all types to activate their social capital. This vertical provides tooling for all forms of experiential content, artifacts and marketplaces for the world’s most creative icons and their fans.
● ORIGYN Luxury is the only digital certification solution guaranteed to prove authenticity using a luxury object’s own biometric features. These digital certificates increase trust between companies and their clients with a paperless solution, guaranteed by ORIGYN, which facilitates the resale of the object. This vertical brings NFTs to life by enabling the object itself to become its own proof of authenticity.
Funding from this round powers the foundation’s mission and contributes to the expansion and continuous improvement of ORIGYN’s verticals as directed by governing token holders. Additionally, it will be used to fund ongoing R&D and onboard the foundation’s growing list of industry partners to the ecosystem.
The ORIGYN authentication platform far surpasses other NFT certification solutions in the market today due to the unique biometric and ownership data included in ORIGYN digital twins, as well as the global guarantee that backs every digital certificate. ORIGYN will officially launch these digital certificates across industry verticals during the first half of 2022. The foundation’s utility token, OGY, will also become publicly tradable in 2022. OGY is necessary to engage with the core services of the platform and is used to create and transact certificates of authenticity.
About the ORIGYN Foundation:
The Swiss non-profit foundation ORIGYN uses intelligent technologies, including computer vision and artificial intelligence, on decentralized computing to identify, authenticate and unlock the powers of ownership for objects of value. As the first digital certification platform built on the Internet Computer (IC), ORIGYN and its verticals generate new forms of value for some of the largest consumer asset classes in the world, including art, collectibles, digital media and luxury goods. Founded in Neuchâtel, Switzerland in October of 2020, ORIGYN operates globally in major technology and blockchain hubs around the world. For more information, visit origyn.ch.
ORIGYN Foundation: Website Twitter LinkedIn Facebook Medium
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211123005882/en/
Contact information
Seamus Conwell
seamus.conwell@150bond.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom